Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

Leukemia is the most common childhood malignancy and acute lymphoblastic leukemia (ALL) represents the largest sub-type. Despite remarkable improvements over the last 40 years, standard therapy fails in 10–20% of newly diagnosed patients. Survival for children with relapsed ALL is poor, and the deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Lindsey M., Gore, Lia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978294/
https://www.ncbi.nlm.nih.gov/pubmed/24744989
http://dx.doi.org/10.3389/fonc.2014.00063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978294/
https://www.ncbi.nlm.nih.gov/pubmed/24744989
http://dx.doi.org/10.3389/fonc.2014.00063

Ejemplares similares